IDEXX Buys AI Scribe Startup to Drive Diagnostic Test Volume

IDEXX Bets on Clinical Documentation to Grow Lab Business

IDEXX Laboratories announced on September 16 that it acquired CoVetAI, a veterinary software company that uses AI to listen during clinical appointments and organize patient information. The deal positions IDEXX to place its diagnostic recommendations directly into the workflow where veterinarians make testing decisions.

The acquisition price was not disclosed, leaving investors to evaluate the strategic logic rather than the financial terms. IDEXX operates more than 10,000 veterinary clinics worldwide on its cloud practice software, giving CoVet immediate distribution. The scribe tool will integrate with IDEXX VetConnect PLUS, the company's diagnostic ordering platform. IDEXX also plans to maintain compatibility with rival practice management systems and competing scribe products, extending reach beyond its existing customer base.

Why it matters

This acquisition reflects a broader trend in healthcare AI: companies that control both the software layer and the underlying service can use automation to increase utilization. For IDEXX, smarter documentation tools could translate directly into higher diagnostic test volumes, the core driver of its recurring revenue model.

Diagnostics Growth Already Strong

IDEXX reported second-quarter results on August 4 showing 10 percent revenue growth, with its recurring diagnostics segment up 11 percent on higher volumes. The company also deployed more than 1,600 inVue Dx analyzers during the quarter, bringing the installed base above 9,000 units. IDEXX markets the inVue line as AI-enabled, signaling that both its software and hardware strategies are converging around intelligent workflow tools.

The company describes the CoVet payoff in future terms, saying the capabilities "can raise diagnostic use over time." That language acknowledges the acquisition is a bet on behavior change rather than an immediate earnings contributor.

Valuation and Investor Positioning

Second-quarter earnings per share rose 18 percent, though 15 percent on a comparable basis after adjusting for tax benefits from stock compensation and currency tailwinds. IDEXX has raised its full-year earnings outlook but noted increased spending on commercial and innovation priorities.

Hedge fund ownership edged up to 63 funds from 62 in the prior quarter, indicating stable institutional interest. Short interest stands at 3.04 percent of float, suggesting minimal bearish sentiment. The stock trades at a forward price-to-earnings ratio of 30.86 as of September 18, according to the source, reflecting expectations for continued growth but leaving limited room for disappointment.

CoVet's compatibility with non-IDEXX practice systems is a double-edged feature. It broadens the addressable market but also allows clinics to adopt the scribe without deepening their relationship with IDEXX's diagnostic ecosystem.

Details of the acquisition were first reported by AI Watch.